Coverage / CLRB / Trade Card

CLRB

Cellectar Biosciences Inc

OPPORTUNISTIC BUY 2026-08-09 Data 34 days old USD 2.57 Healthcare - BiotechnologyAWAIT ENTRY
ACTIONABLEMethodology gates passed
62

Position levels

Currenttoday
USD 2.57
Buy <=wait / entry
USD 2.27
Trim >=take some off
USD 3.20
Thesis breakA confirmed failure of the strategic alternatives process without a near-term tr...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case29%100 / 10029.0
Base case50%62 / 10031.0
Bear case21%10 / 1002.1
Weighted conviction62 / 100 - OPPORTUNISTIC BUY

Top risks

  • Exploration of strategic alternatives including mergers, acquisitions, partnerships and licensing arrangements with Oppenheimer engaged as advisor
  • Q1 2026 EPS beat of -1.33 vs -1.78 estimate (+25.28% surprise)
  • Reliance on third-party collaborators for manufacturing, research and clinical studies exposing company to supply and compliance risks
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.